Cholib

Country: European Union

Language: Croatian

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

fenofibrate, simvastatin

Available from:

Viatris Healthcare Limited

ATC code:

C10BA04

INN (International Name):

fenofibrate, simvastatin

Therapeutic group:

Sredstva za modifikaciju lipida

Therapeutic area:

dislipidemije

Therapeutic indications:

Cholib je indiciran kao dodatna terapija dijeti i tjelovježbi u odraslih bolesnika visokim s mješovitim dislipidemijom za smanjenje triglicerida i povećanje razine HDL C kad LDL C razinama adekvatno upravlja pomoću odgovarajuće doze monoterapije simvastatinom.

Product summary:

Revision: 16

Authorization status:

odobren

Authorization date:

2013-08-26

Patient Information leaflet

                                1
PRILOG I.
SAŽETAK OPISA SVOJSTAVA LIJEKA
2
1.
NAZIV LIJEKA
Cholib 145 mg/20 mg filmom obložene tablete
2.
KVALITATIVNI I KVANTITATIVNI SASTAV
Jedna filmom obložena tableta sadrži 145 mg fenofibrata i 20 mg
simvastatina.
Pomoćna(e) tvari s poznatim učinkom:
Jedna filmom obložena tableta sadrži 160,1 mg laktoze (u obliku
hidrata), 145 mg saharoze, 0,7 mg
lecitina (iz soje (E322)) i 0,17 mg bojila sunset yellow FCF (E110).
Za cjeloviti popis pomoćnih tvari vidjeti dio 6.1.
3.
FARMACEUTSKI OBLIK
Filmom obložena tableta (tableta).
Ovalna, bikonveksna, žućkastosmeđa, filmom obložena tableta s
kosim rubovima i oznakom 145/20
na jednoj strani. Dimenzije su približno 19,3 × 9,3 mm u promjeru, a
masa tablete je oko 734 mg.
4.
KLINIČKI PODACI
4.1
TERAPIJSKE INDIKACIJE
_ _
Cholib je indiciran kao dodatna terapija dijeti i tjelovježbi u
odraslih bolesnika s visokim
kardiovaskularnim rizikom s miješanom dislipidemijom radi smanjivanja
razina triglicerida i
povećavanja razina HDL-C-a kada su razine LDL-C-a odgovarajuće
kontrolirane s odgovarajućom
dozom monoterapije simvastatinom.
4.2
DOZIRANJE I NAČIN PRIMJENE
Sekundarni uzroci hiperlipidemije, kao što je nekontrolirana
šećerna bolest tipa 2, hipotireoza,
nefrotski sindrom, disproteinemija, opstruktivna bolest jetre,
farmakološko liječenje (poput peroralnih
estrogena) i alkoholizam moraju se odgovarajuće liječiti prije
razmatranja terapije Cholibom, a
bolesnici se moraju staviti na standardnu dijetu za snižavanje
kolesterola i triglicerida koju trebaju
nastaviti tijekom liječenja.
Doziranje
Preporučena doza je jedna tableta dnevno. Treba izbjegavati sok od
grejpa (vidjeti dio 4.5).
_ _
Potrebno je pratiti odgovor na terapiju određivanjem vrijednosti
lipida u serumu (ukupni kolesterol
(UK), LDL-C, trigliceridi (TG)).
_Stariji bolesnici (≥65 godina starosti) _
Nije potrebna prilagodba doze. Preporučuje se uobičajena doza, osim
kod smanjene funkcije bubrega s
procijenjenom brzinom glomerularne filtracije <60 ml/min/1,73 m
2
gdje je Cholib k
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
PRILOG I.
SAŽETAK OPISA SVOJSTAVA LIJEKA
2
1.
NAZIV LIJEKA
Cholib 145 mg/20 mg filmom obložene tablete
2.
KVALITATIVNI I KVANTITATIVNI SASTAV
Jedna filmom obložena tableta sadrži 145 mg fenofibrata i 20 mg
simvastatina.
Pomoćna(e) tvari s poznatim učinkom:
Jedna filmom obložena tableta sadrži 160,1 mg laktoze (u obliku
hidrata), 145 mg saharoze, 0,7 mg
lecitina (iz soje (E322)) i 0,17 mg bojila sunset yellow FCF (E110).
Za cjeloviti popis pomoćnih tvari vidjeti dio 6.1.
3.
FARMACEUTSKI OBLIK
Filmom obložena tableta (tableta).
Ovalna, bikonveksna, žućkastosmeđa, filmom obložena tableta s
kosim rubovima i oznakom 145/20
na jednoj strani. Dimenzije su približno 19,3 × 9,3 mm u promjeru, a
masa tablete je oko 734 mg.
4.
KLINIČKI PODACI
4.1
TERAPIJSKE INDIKACIJE
_ _
Cholib je indiciran kao dodatna terapija dijeti i tjelovježbi u
odraslih bolesnika s visokim
kardiovaskularnim rizikom s miješanom dislipidemijom radi smanjivanja
razina triglicerida i
povećavanja razina HDL-C-a kada su razine LDL-C-a odgovarajuće
kontrolirane s odgovarajućom
dozom monoterapije simvastatinom.
4.2
DOZIRANJE I NAČIN PRIMJENE
Sekundarni uzroci hiperlipidemije, kao što je nekontrolirana
šećerna bolest tipa 2, hipotireoza,
nefrotski sindrom, disproteinemija, opstruktivna bolest jetre,
farmakološko liječenje (poput peroralnih
estrogena) i alkoholizam moraju se odgovarajuće liječiti prije
razmatranja terapije Cholibom, a
bolesnici se moraju staviti na standardnu dijetu za snižavanje
kolesterola i triglicerida koju trebaju
nastaviti tijekom liječenja.
Doziranje
Preporučena doza je jedna tableta dnevno. Treba izbjegavati sok od
grejpa (vidjeti dio 4.5).
_ _
Potrebno je pratiti odgovor na terapiju određivanjem vrijednosti
lipida u serumu (ukupni kolesterol
(UK), LDL-C, trigliceridi (TG)).
_Stariji bolesnici (≥65 godina starosti) _
Nije potrebna prilagodba doze. Preporučuje se uobičajena doza, osim
kod smanjene funkcije bubrega s
procijenjenom brzinom glomerularne filtracije <60 ml/min/1,73 m
2
gdje je Cholib k
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 06-03-2024
Summary of Product characteristics Summary of Product characteristics Bulgarian 06-03-2024
Public Assessment Report Public Assessment Report Bulgarian 18-09-2013
Patient Information leaflet Patient Information leaflet Spanish 06-03-2024
Public Assessment Report Public Assessment Report Spanish 18-09-2013
Patient Information leaflet Patient Information leaflet Czech 06-03-2024
Public Assessment Report Public Assessment Report Czech 18-09-2013
Patient Information leaflet Patient Information leaflet Danish 06-03-2024
Public Assessment Report Public Assessment Report Danish 18-09-2013
Patient Information leaflet Patient Information leaflet German 06-03-2024
Public Assessment Report Public Assessment Report German 18-09-2013
Patient Information leaflet Patient Information leaflet Estonian 06-03-2024
Public Assessment Report Public Assessment Report Estonian 18-09-2013
Patient Information leaflet Patient Information leaflet Greek 06-03-2024
Public Assessment Report Public Assessment Report Greek 18-09-2013
Patient Information leaflet Patient Information leaflet English 06-03-2024
Public Assessment Report Public Assessment Report English 18-09-2013
Patient Information leaflet Patient Information leaflet French 06-03-2024
Public Assessment Report Public Assessment Report French 18-09-2013
Patient Information leaflet Patient Information leaflet Italian 06-03-2024
Public Assessment Report Public Assessment Report Italian 18-09-2013
Patient Information leaflet Patient Information leaflet Latvian 06-03-2024
Public Assessment Report Public Assessment Report Latvian 18-09-2013
Patient Information leaflet Patient Information leaflet Lithuanian 06-03-2024
Summary of Product characteristics Summary of Product characteristics Lithuanian 06-03-2024
Public Assessment Report Public Assessment Report Lithuanian 18-09-2013
Patient Information leaflet Patient Information leaflet Hungarian 06-03-2024
Summary of Product characteristics Summary of Product characteristics Hungarian 06-03-2024
Public Assessment Report Public Assessment Report Hungarian 18-09-2013
Patient Information leaflet Patient Information leaflet Maltese 06-03-2024
Public Assessment Report Public Assessment Report Maltese 18-09-2013
Patient Information leaflet Patient Information leaflet Dutch 06-03-2024
Public Assessment Report Public Assessment Report Dutch 18-09-2013
Patient Information leaflet Patient Information leaflet Polish 06-03-2024
Public Assessment Report Public Assessment Report Polish 18-09-2013
Patient Information leaflet Patient Information leaflet Portuguese 06-03-2024
Summary of Product characteristics Summary of Product characteristics Portuguese 06-03-2024
Public Assessment Report Public Assessment Report Portuguese 18-09-2013
Patient Information leaflet Patient Information leaflet Romanian 06-03-2024
Public Assessment Report Public Assessment Report Romanian 18-09-2013
Patient Information leaflet Patient Information leaflet Slovak 06-03-2024
Public Assessment Report Public Assessment Report Slovak 18-09-2013
Patient Information leaflet Patient Information leaflet Slovenian 06-03-2024
Summary of Product characteristics Summary of Product characteristics Slovenian 06-03-2024
Public Assessment Report Public Assessment Report Slovenian 18-09-2013
Patient Information leaflet Patient Information leaflet Finnish 06-03-2024
Public Assessment Report Public Assessment Report Finnish 18-09-2013
Patient Information leaflet Patient Information leaflet Swedish 06-03-2024
Public Assessment Report Public Assessment Report Swedish 18-09-2013
Patient Information leaflet Patient Information leaflet Norwegian 06-03-2024
Summary of Product characteristics Summary of Product characteristics Norwegian 06-03-2024
Patient Information leaflet Patient Information leaflet Icelandic 06-03-2024
Summary of Product characteristics Summary of Product characteristics Icelandic 06-03-2024

Search alerts related to this product

View documents history